Publication Name	World Journal of Hepatology
Manuscript ID	13916
Country	Japan

Received	2014-09-09 08:39
Peer-Review Started	2014-09-10 08:26
To Make the First Decision	2014-12-26 13:06
Return for Revision	2014-12-31 09:29
Revised	2015-01-08 14:45
Second Decision	2015-01-28 11:36
Accepted by Journal Editor-in-Chief	2015-01-29 16:24
Accepted by Executive Editor-in-Chief	2015-02-09 09:53
Articles in Press	2015-02-09 09:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-05-04 09:18
Publish the Manuscript Online	2015-05-19 17:28

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Antiviral therapies for chronic hepatitis C virus infection with cirrhosis
Manuscript Source	Invited Manuscript
All Author List	Shingo Nakamoto, Tatsuo Kanda, Hiroshi Shirasawa and Osamu Yokosuka
Funding Agency and Grant Number
Corresponding Author	Tatsuo Kanda, MD, PhD, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
Key Words	Hepatitis C virus; Hepatocellular carcinoma; Interferon-free regimen; Liver cirrhosis; Direct-acting antiviral agent
Core Tip	In general, patients with cirrhosis who are infected with hepatitis C virus (HCV) are at a higher risk for the development of hepatocellular carcinoma (HCC) compared with patients without cirrhosis. Antiviral treatments for patients with cirrhosis and HCV may reduce the occurrence of HCC and/or prevent the progression to hepatic failure. In this review, we discussed the sustained virological response (SVR) rates of interferon-containing and interferon-free regimens for these patients. Recent advances in the development of direct-acting antivirals against HCV have improved the SVR rates and have reduced the occurrence of adverse events during treatment. Interferon-free regimens might improve the prognosis of patients with cirrhosis and HCV.
Publish Date	2015-05-19 17:28
Citation	Nakamoto S, Kanda T, Shirasawa H, Yokosuka O. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol 2015; 7(8): 1133-1141
URL	http://www.wjgnet.com/1948-5182/full/v7/i8/1133.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i8.1133

Full Article (PDF)	WJH-7-1133.pdf
Full Article (Word)	WJH-7-1133.doc
Manuscript File	13916-Review.doc
Answering Reviewers	13916-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13916-Conflict-of-interest statement.pdf
Copyright License Agreement	13916-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	13916-Language certificate.pdf
Peer-review Report	13916-Peer-review(s).pdf
Scientific Misconduct Check	13916-Scientific misconduct check.pdf
Scientific Editor Work List	13916-Scientific editor work list.pdf